Navigation Links
PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
Date:12/2/2008

Major biopharmaceutical companies with substantial internal mammalian cell culture capability are forecast to have adequate internal manufacturing capacity. Contract mammalian cell culture manufacturers (CMOs) however, are likely to feel the pressure of increased utilization rates. For these CMOs and biopharmaceutical companies depending on them, understanding critical demand drivers, market factors and manufacturing trends is instrumental to making effective strategic supply decisions.

Fairfax, VA (PRWEB) December 2, 2008 -- Major biopharmaceutical companies with substantial internal mammalian cell culture capability are forecast to have adequate internal manufacturing capacity. Contract mammalian cell culture manufacturers (CMOs) however, are likely to feel the pressure of increased utilization rates. For these CMOs and biopharmaceutical companies depending on them, understanding critical demand drivers, market factors and manufacturing trends is instrumental to making effective strategic supply decisions.

"Cell Culture Manufacturing Capacity: Trends and Outlook through 2013" provides a timely and detailed examination of these issues. In this definitive report, foremost experts BioProcess Technology Consultants and PharmSource Information Services provide an extensive supply and demand analysis in addition to in-depth recommendations for the cell culture industry. Detailed data points include: product pipeline analysis, probable product success rates, time to market, API requirements, current and planned capacity, process yields and the potential impact of technology advances including biosimilars. "This report offers valuable strategic insight to support critical 'make or buy' decisions for mammalian cell culture manufacturers, key recommendations for capital investments and clear pricing strategy direction for the biologics contract manufacturing industry," comments BioProcess Technology Consultants president and founder Howard L. Levine, Ph.D. PharmSource president and founder, Jim Miller, concurs, "At a time of so much uncertainty in the biopharmaceutical industry, this analysis provides decision makers with the in-depth understanding they need to may critical API supply decisions."

The $4,950 report will be offered at the $700 pre-order discount price of $4,250 through December 15, 2008. For more detailed information and ordering instructions visit: http://www.pharmsource.com/forms.cfm?id=32.

About the Authors:
Founded in 1994, BioProcess Technology Consultants, Inc. is the leading providers of strategic, technical, operational, and regulatory consulting services to the biopharmaceutical industry and the industry's foremost expert on cell culture manufacturing. The company specializes in helping clients speed their products from clone to commercial®. Visit BioProcess Technology Consultants on the web at http://www.bioprocessconsultants.com or contact them at 978-266-9113.

PharmSource Information Services, Inc. is a respected provider of contract drug development and manufacturing intelligence. Since 1996 PharmSource has assisted Biotechnology and Pharmaceutical companies with the implementation and management of sourcing strategies and tactics through insightful publications, analyses and intelligence services. Visit PharmSource on the web at http://www.pharmsource.com or contact them at 703-383-4903.

###

Read the full story at http://www.prweb.com/releases/2008/12/prweb1691734.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmSource President Moderates Videocast on Outsourcing to Asia at AAPS
2. PharmSource Introduces Proprietary Resource for Identifying New Business Opportunities in Bio/Pharma
3. Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement
4. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
5. Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
6. Science Teachers Tour Ventrias Bioprocessing Facility
7. Thermo Fisher Scientific to Expand Manufacturing Operation for Single-Use Bioprocessing Containers
8. 2010 Japan Prize to Honor Scientists and Researchers in Industrial Production/Production Technology and Biological Production/Environment Fields
9. New Radiation-Blocking Medical Garments Introduced at RSNA Meeting in Chicago : Demron-M Technology Provides Total Protection in a Lightweight, Durable, Flexible Fabric
10. Micromet Added to NASDAQ Biotechnology Index
11. Aldrich(R) Releases Materials Science Catalog That Includes Products to Advance Sustainable Energy and Nanotechnology Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... San Diego, CA (PRWEB) , ... May 20, ... ... decision support tool that helps avoid the lengthy trial and error process by ... for patients. It can also strengthen the doctor-patient relationship through a personalized ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs ... the Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old ... failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl ... CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal ... at Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior ...
(Date:5/18/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... May 17, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... the Chairman of the UDIs and Traceability for Medical Devices conference in Brussels, ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):